Doxorubicin Efficacy Improved, Cardiotoxicity Reduced With Adjuvant Fidarest for Colon Cancer
The AR inhibitor fidarestat is effective as adjuvant therapy to enhance doxorubicin sensitivity of colorectal cancer cells and to reduce cardiotoxicity associated with the drug.